IN8bio, Inc. (INAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases. Its lead candidates include INB-400, a Phase 2 program for newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell candidate in Phase 1 for GBM; and INB-100, an allogeneic candidate in Phase 1 for acute myeloid leukemia. The company is also advancing INB-619, a next-generation T cell engager for autoimmune indications.
Gamma-delta T cells are a specialized immune-cell population that can distinguish healthy from diseased tissue, and IN8bio positions its platform as a differentiated approach to cell therapy. Investors follow the stock for its oncology data readouts, autoimmune pipeline expansion, and potential regulatory milestones. Like many early-stage biotechs, IN8bio is pre-revenue and depends on external financing to fund its programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, IN8bio shares declined approximately 28%, moving from a closing price near $1.20 to roughly $0.86. The move was largely one-directional, with the stock breaching the $1.00 level in late October and continuing to drift lower into mid-November.
The quarterly picture is similar in magnitude but tells a more volatile story. Three months earlier, IN8bio traded around $1.18; the stock climbed to roughly $1.33 by late September before reversing sharply, ending the quarter down about 27%. Against its 52-week range of approximately $0.80 to $2.73, the stock now sits near the lower end of that band. From what I see, the pattern reflects typical pressure on micro-cap names in this sector.
INAB's recent decline has not been tied to a single negative headline but rather to persistent selling pressure in a thinly traded, micro-cap security. The company reported third-quarter 2026 results in early November, posting a net loss per share of $0.24 that was narrower than consensus estimates, along with pipeline updates that included recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers. Despite the better-than-expected loss, the stock continued to slide, reflecting broader caution around a pre-revenue biotech's cash runway and dilution risk.
The move below $1.00 also drew attention to Nasdaq minimum bid price requirements, an issue that often weighs on sentiment for sub-$1.00 listings. Meanwhile, constructive analyst actions — including H.C. Wainwright reiterating a Buy rating with a $6 price target and JonesTrading maintaining a Buy with a $5 target — were not enough to offset the downward momentum. I’m watching this closely as liquidity remains a key variable.
The quarter's broader narrative is one of a strong late-summer rally followed by a sharp reversal. In September, IN8bio strengthened its research leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development, a move that reinforced its gamma-delta T cell engager expertise. Investor conferences and pipeline presentations supported the stock into late September, when shares touched roughly $1.33.
From that peak, sentiment deteriorated as the market refocused on the fundamentals facing an early-stage developer: no product revenue, an ongoing need for capital, and binary clinical and regulatory outcomes. Thin average daily volume amplified price swings, and the steady slide through October and November erased the earlier gains, leaving the stock down about 27% for the quarter.
Looking ahead, the most important factors for IN8bio are clinical and financial. Investors should monitor updated glioblastoma data from the INB-400 and INB-200 programs, as well as any regulatory guidance on a potential registrational path. Preclinical and early clinical progress for the INB-619 T cell engager in autoimmune disease is another key catalyst, as is the company's ability to secure additional financing to extend its cash runway. Analyst price targets remain well above current levels, but realization depends on successful data readouts and funding execution. Broader sector conditions — including investor appetite for clinical-stage biotech risk — will also continue to influence the stock's volatility.
In my own workflow, Tickeron’s AI Trading Bots have become a useful way to review systematic strategies that might align with names like INAB. The platform offers hundreds of automated approaches across thousands of tickers, and the trending section surfaces only the top-performing and most relevant ones for quick reference. It helps me compare momentum and trend-following signals without replacing fundamental research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Be on the lookout for a price bounce soon.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INAB's RSI Oscillator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +13.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where INAB advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INAB as a result. In 77 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INAB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
INAB moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INAB crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for INAB entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.497) is normal, around the industry mean (3.586). P/E Ratio (-0.713) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. INAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology